Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nymox Pharmaceutical has reported new positive data from Phase 3 study, designed to evaluate the safety and efficacy of the reinjection of NX-1207 for benign prostatic hyperplasia (BPH).
Subscribe to our email newsletter
The NX02-0020 study participants included 192 repeatedly treated men, who were a part of completed NX02-0014 and NX02-0016 Phase 2 trials or taking part in the NX02-0017 and NX02-0018 trials that are still going on.
Nymox CEO Paul Averback said, "This degree of long-term improvement is unprecedented in this condition considering that it is a simple, painless and safe injection with no sexual side effects, and that it has been demonstrated in a large series of treated patients."
Study assessed the improvement in the American Urological Association BPH Symptom Index Score for a period of 26 months, which is the mean duration from drug injection till final evaluation.
NX02-0020 study reported mean overall improvement of 7.6 points, while the company expects to conduct further analysis subsequent to the unblinding of NX02-0017 and NX02-0018 trials.
Positive safety results were obtained for NX-1207 re-injection in the six month primary endpoint, without any related adverse events.